Table 1. Baseline clinicopathological characteristics of 114 MSS stage II and III colon cancer patients.
| Overall (n = 114) | Stage II (n= 57) | Stage III (n = 57) | ||
|---|---|---|---|---|
| Sex | Male | 67 (58.8) | 31 (54.4) | 36 (63.2) |
| Female | 47 (41.2) | 26 (45.6) | 21 (36.8) | |
| Age (years) | Mean (s.d.) | 69.2 (11.6) | 72,0 (12.4) | 66.4 (10.1) |
| Median (range) | 70.1 (28.5–91.3) | 74.4 (28.5–91.3) | 66.6 (40.9–83.3) | |
| Tumor location | Right sided | 46 (40.4) | 19 (33.3) | 27 (47.4) |
| Left sided | 68 (59.6) | 38 (66.7) | 30 (52.6) | |
| Tumor size (mm) | Mean (s.d.) | 36.8 (16.3) | 39.3 (19.4) | 34.4 (12.4) |
| Tumor stage | T1 | 1 (0.9) | 0 (0.0) | 1 (1.8) |
| T2 | 7 (6.1) | 0 (0.0) | 7 (12.3) | |
| T3 | 96 (84.2) | 53 (93.0) | 43 (75.4) | |
| T4 | 10 (8.8) | 4 (7.0) | 6 (10.5) | |
| Nodal stage | N0 | 57 (50.0) | 57 (100.0) | 0 (0.0) |
| N1 | 36 (31.6) | 0 (0.0) | 36 (63.2) | |
| N2 | 21 (18.4) | 0 (0.0) | 21 (36.8) | |
| No. of nodes examined | Mean (s.d.) | 9.0 (4.1) | 7.9 (3.6) | 10.1 (4.4) |
| Histological grade | Well | 8 (7.02) | 6 (10.5) | 2 (3.5) |
| Moderate | 99 (86.8) | 49 (86.0) | 50 (87.7) | |
| Poor | 7 (6.1) | 2 (3.5) | 5 (8.8) | |
| Mucinous | No | 96 (84.2) | 45 (78.9) | 51 (89.5) |
| differentiation | Yes | 18 (15.8) | 12 (21.1) | 6 (10.5) |
| Ulceration | Absent | 21 (18.4) | 12 (21.1) | 9 (15.8) |
| Present | 93 (81.6) | 45 (78.9) | 48 (84.2) | |
| Angioinvasion | Absent | 83 (72.8) | 49 (86.0) | 34 (59.6) |
| Present | 31 (27.2) | 8 (14.0) | 23 (40.4) | |
| Adjuvant therapy | No | 56 (49.1) | 55 (96.5) | 1 (1.8) |
| Yes* | 58 (50.9) | 2 (3.5) | 56 (98.2) | |
| Recurrent Disease | No | 65 (57.0) | 35 (61.4) | 30 (52.6) |
| Yes | 49 (43.0) | 22 (38.6) | 27 (47.4) | |
| Follow-up (months) | Median (range) | 57.3 (4.3–129.2) | 61.8 (11.5–129.2) | 53,6 (4.3–127.4) |
Values in parentheses are percentages unless stated otherwise.
*
Adjuvant chemotherapy: 5-fluorouracil and leucovorin (5-FU/LV) mono therapy.